AlphAIAlphAI — Financial news for AI agents
biospace.comSEP 282 min read$BMY

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb (BMY) presented Phase 3 trial results showing ZENBEXUS (iberdomide) with daratumumab and dexamethasone doubled minimal residual disease-negative complete response rates (41.1% vs. 20.7%) compared to standard treatment in relapsed or refractory multiple myeloma. The data were published in The Lancet Oncology and presented at IMS 2026. The FDA granted accelerated approval for ZENBEXUS in this indication on August 13.

Original reporting
biospace.com
Published Sep 28, 2026, 2:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma — source image
Source · biospace.com
Decision brief

The 30-second read

$BMYBullishHigh
01

Why it matters

The data demonstrate a clear efficacy advantage, likely prompting re‑rating of BMY by analysts and prompting investor buying.

02

Market read

First‑time disclosure of pivotal trial results for a late‑stage oncology drug; high relevance for biotech investors.

03

What to watch

Potential competition from other oral IMiDs and the need for confirmatory PFS data could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

The article reports the first presentation of pivotal Phase 3 data for ZENBEXUS (iberdomide) in relapsed/refractory multiple myeloma, alongside FDA accelerated‑approval status.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Bristol Myers Squibb presented Phase 3 EXCALIBER-RRMM trial results showing a 41.1% MRD‑negative CR rate versus 20.7% for the comparator, indicating a strong efficacy advantage.

Expected impact

upward pressure as the market incorporates the efficacy advantage and accelerated‑approval status.

Evidence & confidence

First disclosure of pivotal trial outcomes for a late‑stage oncology asset; large‑cap biotech with material commercial upside.

Market effects

Sector

Strengthens the multiple‑myeloma and broader immuno‑oncology sector, may boost peer biotech valuations.

Regional

Supports US biotech sentiment and could influence regional biotech ETFs.

Global

Adds a new effective therapy to the global oncology pipeline, affecting worldwide treatment landscapes.

Counterpoint

What could challenge this read

If safety concerns, especially high neutropenia rates, limit adoption, the stock may not rally as expected.

Key entities

  • company
    Bristol Myers Squibb

    US‑listed pharmaceutical company developing ZENBEXUS.

  • drug
    ZENBEXUS (iberdomide)

    Oral immunomodulatory agent evaluated in the EXCALIBER‑RRMM trial.

Read at source← All news

Related articles

SEP 28
$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Bristol Myers Squibb (BMY) awaits an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Egetis Therapeutics (EGTX) faces a Sept. 28 decision for Emcitate for MCT8 deficiency. Scholar Rock (SRRK), Biofrontera (BFRI), and Mirum Pharmaceuticals (MIRM) received early FDA approvals for their respective drugs. Mirum's shares rose 3% in pre-market trading.

newsable.asianetnews.com2 min
SEP 28
$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals

Bristol Myers Squibb (BMY) and Egetis Therapeutics (EGTX) await FDA decisions on drug expansions. Biofrontera (BFRI), Scholar Rock (SRRK), and Mirum Pharmaceuticals (MIRM) received early approvals. BMY's Camzyos, if approved, would be the first cardiac myosin inhibitor for adolescents with oHCM. EGTX's Emcitate could be the first FDA-approved treatment for MCT8 deficiency. SRRK and BFRI shares declined post-approval, while MIRM shares rose.

stocktwits.com2 min
SEP 26
$NVSMedAI 8/10

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

Novartis (NVS) and Bristol-Myers Squibb (BMY) paused CAR-T cell therapy trials. NVS halted eight studies after three patient deaths, while BMY paused enrollment due to reversible inflammatory events. NVS's oncology trials continue. BMY's situation is less severe, with no deaths reported. Both companies face safety and development risks, with potential delays and increased costs.

insidermonkey.com3 min
SEP 25
$BMYMedAI 8/10

Bristol Myers Squibb Presents First Data From Phase 3 EXCALIBER-RRMM Trial Evaluating Iberdomide Combination in Multiple Myeloma

Bristol Myers Squibb (BMS) presented Phase 3 EXCALIBER-RRMM trial data showing iberdomide (ZENBEXUS) with daratumumab and dexamethasone achieved higher MRD-negative CR rates (41%) vs. standard therapy (21%) in relapsed/refractory multiple myeloma. The FDA granted accelerated approval for this combination in August 2026. Trial continues evaluating PFS and safety.

oncodaily.com2 min
SEP 22
$BMYLowAI 8/10

Major NJ Pharmaceutical Company Lays Off Hundreds

Bristol Myers Squibb will lay off hundreds of employees in New Jersey by May 2027, part of a restructuring plan to save $2 billion by 2027. The company has already cut over 1,700 positions since January 2025 and saved $1 billion. Bristol Myers Squibb reported $48.2 billion in 2025 revenue and projects $46-47.5 billion for 2026.

patch.com2 min